Dr Steven A. Kemp
Senior Research Associate
Since March 2023, I have been working with the Lythgoe group as a Senior Research Associate at the Pandemic Sciences Institute.
My primary areas of focus are Microbiology, Virology, and Population Genetics. I have worked in more than 10 different countries across the world, working on antimicrobial resistance, and investigating HIV drug resistance alongside the PANGEA consortium.
In my current role with the Lythgoe group, I am actively engaged in studying the transmission and evolution of SARS-CoV-2, utilising data from more than 225000 households across the ONS COVID-19 Infection Survey.
An interesting highlight of my career is being part of the team that first identified the Alpha variant of COVID-19.
During these difficult times, I remain dedicated to enhancing our understanding of viruses and their effects on human populations, as well as being particularly open to consulting opportunities with pharmaceuticals, research and innovation.
HIV transmission dynamics and population-wide drug resistance in rural South Africa.
Gupta R. et al, (2023), Res Sq
Population dynamics of HIV drug resistance among pre-treatment and treatment-experienced persons with HIV during treatment scale-up in Uganda: a population-based longitudinal study
Martin MA. et al, (2023)
Atypical B cells and impaired SARS-CoV-2 neutralization following heterologous vaccination in the elderly.
Ferreira IATM. et al, (2023), Cell reports, 42
Limited emergence of resistance to integrase strand transfer inhibitors (INSTIs) in ART-experienced participants failing dolutegravir-based antiretroviral therapy: a cross-sectional analysis of a Northeast Nigerian cohort.
Abdullahi A. et al, (2023), The Journal of antimicrobial chemotherapy, 78, 2000 - 2007
HIV escape and resistance in the central nervous system in treatment experienced South Africans
Collier D. et al, (2023)